cyp1a1, cyp1a2, sult1a1 and sult1e1 allelic polymorphism in case of genital endometriosis

Clicks: 160
ID: 195147
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #12 of 23 articles by views in microsystems and nanoengineering

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
The efficacy of various genital endometriosis treatment schemes has been analyzed. It is reasonable to use gestagens and GnRH agonists for the treatment of pelvic pain syndrome. The frequency of dysmenorrhea relief in women with endometriosis treated with any hormonal therapy is similar. Pregnancy is most often registered, if GnRH agonists and COCs are included into combination therapy schemes. Up-to-date molecular and genetic analyses reveal that women predisposed to genital endometriosis possess Allele G and Genotypes AG and GG of the polymorphic option A-4889G of the CYP1A1 gene and Allele A and Genotypes CA and AA of the polymorphic option C-734A of the CYP1A2 gene. The polymorphism of the promoter regions of the SULT1A1 (G-638A) and SULT1E1 (C-174T) genes is not associated with genital endometriosis in women.
Reference Key
kublinskiy2016vcyp1a1, Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Konstantin Sergeevich Kublinskiy
Journal microsystems and nanoengineering
Year 2016
DOI
10.12731/wsd-2016-1-36-52
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.